Long-acting reversible contraception, such as hormonal and non-hormonal intrauterine devices (IUDs) and hormonal implants, have been proven safe and effective for adolescent patients.
Risk-reducing bilateral salpingo-oophorectomy can reduce the risk of ovarian cancer for BRCA1 and BRCA2 carriers, but the surgery leads to early menopause. Little is known how undergoing the surgery will affect cognition in women who undergo the procedure. In this featured study, researchers share new findings.
Pregnancy, childbirth, and postpartum are periods of dramatic hormonal and physiologic changes that heighten susceptibility to environmental chemicals, including endocrine disrupting chemicals. This study examines whether endocrine disrupting chemicals can influence hormonal shifts during pregnancy as well as contribute to postpartum depression.
Thyrotropin regulates the production of thyroid hormones and their levels during gestation can have a significant effect on pregnancy outcomes. In this featured study from JAMA Network Open, researchers show how low and high maternal thyrotropin levels can increase the risk for adverse pregnancy outcomes.
Excessive urination at night, or nocturia, is not uncommon in postmenopausal women. There are a number of treatment options available but with varying degrees of success.
In this clinical practice review correspondence recently published in the Journal of Clinical Endocrine and Metabolism, physicians challenge some of the standard prescribing guidance for gender affirming hormone therapy.
The percentage of postmenopausal women experiencing nocturia two or more times per night was lower among those who selected systemic hormone treatment compared with no treatment.
Erythrocytosis is a side effect of testosterone therapy that can increase the risk of blood clots. In this featured study, Dutch researchers conducted a 20-year follow-up in adult trans men receiving testosterone therapy finding dangerously high hematocrit levels in some patients.
Estrogens can promote breast cancer but pregnancy reduces the risk of breast cancer. In this study, researchers from the University of Massachusetts at Amherst explore whether environmental chemicals with estrogen receptor agonist properties can promote or reduce the protective effects of pregnancy on breast cancer.
Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.